Legionella Testing Market (2026 - 2033)

Legionella Testing Market Summary

Legionella can cause Legionellosis, a respiratory disorder (a form of pneumonia). It requires intensive care and hospitalization; hence, it is considered one of the public health concerns. The rising prevalence of bacteria-driven diseases and the increasing inclination among governments to incorporate programs to protect public health are expected to fuel the growth of this market. The growing new incidences of Legionnaires disease reported in multiple regions, especially in Europe, are leading to growth in demand for effective legionella testing solutions. For instance, according to the Communicable Disease Threats Report by the European Center for Disease Prevention and Control for week 9, 22-28 February 2025, Austria experienced an outbreak of Legionnaires in Vorarlberg.

Numerous countries in Europe have experienced such outbreaks. For instance, in 2024, 49 cases and 3 deaths associated with the Legionnaires outbreak were reported in Lombardy, Italy, whereas London, UK, experienced 30 cases and 2 deaths. Such incidences result in increasing awareness regarding timely interventions and significant steps by local authorities to limit the consequences of outbreaks. These factors are likely to fuel growth for this market.

Market Dynamics

The Legionella Testing Market is witnessing growth driven by increasing regulatory emphasis on water quality management, rising incidence of Legionnaires’ disease, and expanding implementation of preventive monitoring programs across healthcare facilities, hospitality establishments, commercial buildings, and industrial infrastructure. Demand for Legionella testing solutions is supported by the need for early detection and risk mitigation, encouraging the adoption of culture methods, urinary antigen tests, and molecular diagnostics. Market participants are investing in technologies that improve testing accuracy, reduce turnaround time, and support compliance with water safety standards. The market is benefiting from growing focus on environmental surveillance and water management programs designed to reduce contamination risks and improve public health outcomes. Moreover, companies are strengthening their molecular testing portfolios through strategic acquisitions and technology expansion initiatives. For instance, in September 2024, LuminUltra announced the acquisition of Genomadix's Legionella testing business assets and commercialization rights for the Genomadix Cube qPCR platform. The acquisition enhanced rapid field-based Legionella detection capabilities, supporting broader adoption of molecular testing solutions and reinforcing demand for advanced water monitoring technologies. Continued regulatory oversight and diagnostic innovation are expected to support market growth.

Market Concentration & Characteristics 

Market growth stage is high, and pace of the market growth is accelerating . The legionella testing industry is characterized by a medium degree of innovation owing to rapid technological advancements and increasing demand for novel diagnostic technologies. Innovation is mainly driven by the increasing investment by biotechnology companies and organizations operating in diagnostic solutions.

The legionella testing market has been experiencing moderate levels of mergers and acquisitions. The key strategic advancements associated with acquisitions are mainly driven by the initiatives embraced by key market participants and large enterprises to strengthen the market positioning. For instance, in September 2024, LuminUltra, one of the market participants in the biological diagnostic testing industry, acquired legionella testing business assets of Canada-based biotech company Genomadix Inc.

The legionella testing market experiences high degree impact of regulatory scenario. The legionella testing solutions are subjected to the health and safety regulations, standards for medical devices and others regulatory requirements. The threat of substitute products primarily stimulates from inability of traditional testing solutions to identify dead and live bacteria. Innovation-based new product launches equipped with advanced technology features are expected to capture greater market share in coming years.

Analyst Perspective

The Legionella Testing Market is positioned for steady growth, supported by increasing regulatory focus on water safety, rising incidence of Legionnaires’ disease, and growing implementation of preventive water management programs across healthcare, commercial, and industrial facilities. The market is witnessing a shift toward rapid molecular diagnostics, particularly PCR based technologies, due to their ability to deliver accurate and timely results. Demand for routine environmental surveillance and compliance driven testing is strengthening adoption across developed markets. Ongoing advancements in diagnostic methods, expanding awareness of waterborne disease prevention, and increasing investments in monitoring infrastructure are expected to support continued market expansion throughout the forecast period.

Type Insights

Based on Type, the water testing segment led the market with the largest revenue share of 76.2% in 2025. The factors contributing to the segment growth primarily include government laws that mandate the testing for Legionella. For instance, in numerous European countries, authorities implement Legionella testing regulations. Greater turnaround time is one of the key drawbacks of traditional testing methods, as these tests can take weeks to deliver results, which reduces the possibility of timely intervention. The absence of adequate diagnostics can lead to presumptive treatment or delay it. It can further hamper the treatment measures and cause outbreaks. Therefore, there is a need for the development of new and advanced diagnostic tools.

Traditional testing methods are labor-intensive and involve manual interference, which can cause contamination and affect the outputs. Advancements associated with diagnostic technologies in automation and digitization are responsible for market growth. Automation facilitates up to 50% timesaving in diagnostic procedures, as it reduces the burden of manual efforts. In addition, results are reliable, precise, and sensitive. Diagnostic lab automation generates standardized and reproducible results. Therefore, advanced rapid diagnostic methods are gaining popularity, and their demand is expected to expand in the coming years. However, a limited number of manufacturing companies can challenge market growth.

The IVD testing segment is expected to experience significant growth over the forecast period. Urinary antigen tests and PCR are widely used for legionella testing, combined with traditional culture methods. Reduced turnaround time associated with IVD testing facilitates quick diagnosis and timely interventions. These aspects are expected to support the growth of this segment.

End Use Insights

Based on end use, the PCR segment led the market with the largest revenue share of 37.4% in 2025. PCR is mainly preferred for its rapid pace, less turnaround time, sensitivity, and capacity to identify both viable and non-viable bacteria. PCR offers high sensitivity and quick detection capabilities, enabling accurate identification of Legionella bacteria quickly. Advancements in molecular diagnostics and increasing regulatory support for incorporating faster and more reliable testing methods drive the growth of this segment.

The microbial culture segment is expected to grow significantly from 2025 to 2030. Microbial culture offers high specificity and sensitivity, accurately identifying Legionella bacteria. Regulatory guidelines often recommend or require its use, ensuring water safety in various settings. It is increasingly used in routine legionella testing and case confirmations. The method is also used in risk assessment and regular water testing.

Regional Insights

North America dominated the Legionella Testing Market with the largest revenue share of 37.1% in 2025. The increasing incidence of Legionnaires' cases of pneumonia-like illness caused by the Legionella bacteria is a major driver for this regional market. Rising awareness regarding the risks associated with disease, stringent regulations, and growing investments in R&D to develop innovative testing solutions are likely to drive growth in this market.

U.S. Legionella Testing Market Trends

The Legionella Testing Market in the U.S. held the largest share in the North America region in 2025 with the largest revenue share due to its strict water safety stipulations, robust healthcare infrastructure, and high awareness of Legionnaires' disease. The increasing availability of advanced diagnostic solutions and the significant focus of government authorities on protecting public health and welfare are expected to add lucrative growth opportunities to this market.

Europe Legionella Testing Market Trends

Europe dominated the global legionella testing industry and accounted for the largest revenue share of 39.7% in 2024. The governments in some countries, such as the UK and Germany, have made Legionella testing mandatory to protect public health. This is primarily due to the high levels of awareness regarding Legionellosis related diseases and associated risks.

The UK legionella testing market held the largest revenue share of the regional market in 2024. Key factor influencing the growth of this market is increasing prevalence of Legionnaires disease driven by easy spread of bacteria, presence of multiple purpose-built water systems especially in public buildings such as hospitals, government buildings, and hotels.

Asia Pacific Legionella Testing Market Trends

Asia Pacific is expected to grow at the fastest CAGR of 9.5% during the forecast period. The rising geriatric population in this region, which is more prone to infections, is expected to develop a greater demand for diagnostic solutions related to bacteria-driven diseases. In addition, increasing disposable income and growing penetration of Legionella testing products via a strong distribution network of global market participants are expected to drive market growth over the forecast period. Significant enhancements associated with healthcare infrastructure in the region, the focus of multiple countries such as China and India to provide public health improvement support, and the growing availability of advanced solutions are anticipated to generate greater opportunities for this market.

China held a substantial revenue share of regional legionella testing industry in 2024 owing to rapid urbanization, industrialization and the increasing awareness of waterborne diseases. The focus of local authorities on the implementation of preventive measures is also driving the growth of this market.

Key Legionella Testing Company Insights

Key players in the global legionella testing industry include Abbott, Beckman Coulter, Inc. (Danaher Corporation), BD, BIOMÉRIEUX, F. Hoffmann-La Roche Ltd. and others. The key market participants focus on innovation, research and development investment, and the delivery of advanced technology-driven solutions to strengthen market positioning.

• Abbott is one of the global market participants in diagnostics and it plays a significant role in the legionella testing market. It offers rapid diagnostic tools such as the BinaxNOW Legionella Urinary Antigen Card for aiding the presumptive diagnosis of disease.

• Beckman Coulter, Inc. (Danaher Corporation) specializes in products associated with biomedical testing. It offers microbiology panels, systems, and analyzers. It also provides products and reagents which are utilized in the Legionella urinary antigen testing.

Key Legionella Testing Companies

The following key companies have been profiled for this study on the legionella testing market.

• Abbott

• Beckman Coulter, Inc. (Danaher Corporation)

• BD

• Bio-Rad Laboratories, Inc.

• BIOMÉRIEUX

• Eiken Chemical Co., Ltd.

• Hologic, Inc

• Pro Lab Diagnostics Inc.

• QIAGEN

• F. Hoffmann-La Roche Ltd.

• Takara Bio Inc.

• Thermo Fisher Scientific Inc.

Competitive Benchmarking

Recent Developments

• In September 2024, LuminUltra Technologies Ltd., a Canadian molecular diagnostics company, acquired the Legionella testing assets of Genomadix Inc. This acquisition includes the Genomadix Cube qPCR platform, a portable device capable of delivering Legionella detection results in under an hour with laboratory-grade sensitivity

• In May 2024, Dubai Central Laboratory, affiliated with Dubai Municipality, recently adopted a novel artificial intelligence (AI) powered technology developed to identify Legionella pulmonary bacteria which causes numerous acute respiratory infections. The first-of-its-kind application in the region is expected to support the growing demand for effective testing technologies equipped with less turnaround time.

Legionella Testing Market Report Scope

Global Legionella Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global legionella testing industry report based on type, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Water Testing

  • IVD Testing

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Microbial Culture

  • Direct Fluorescent Antibody (DFA) Stain

  • PCR

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

Segment Definition

Estimation Model

The legionella testing market was estimated using a bottom-up methodology that involved identifying leading market participants, evaluating their Legionella testing product portfolios, and assessing the contribution of diagnostic assays, instruments, consumables, and associated testing services. Market estimates were developed across key testing technologies and application segments based on adoption trends, utilization patterns, and end user demand. The overall market size was established through the aggregation of segment level estimates and further validated through an assessment of the market share of key manufacturers. The findings were corroborated using company annual reports, regulatory and public health publications, industry databases, scientific literature, and primary discussions with industry experts and stakeholders across the value chain.

Delivered Customizations

This report has been delivered with the following In-depth customizations